Spain

Spain

HBV elimination goal
Yes
Year of HBV elimination goal
No data
HBV Action Plan
No
HCV elimination goal
Yes
Year of HCV elimination goal
No data
HCV Action Plan
Yes
Prevalence
Prevalence of chronic HBV (HBsAg+) (%)
0.22
2018 , Survey/reported
(0 - 0)
Ministerio de Sanidad, Servicios Sociales e Igualidad (2020). 2ND ESTUDIO DE SEROPREVALENCIA EN ESPANA. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualidad.
Prevalence of chronic HBV (HBsAg+), Children < 5 yrs
No data
Prevalence
Prevalence of chronic HCV (RNA+/cAg) (%)
No data
Prevalence of chronic HCV (RNA+/cAg), Persons who inject drugs
66
2015 , Survey/reported
EMCDDA; Ministry of Health
Mortality
HBV-related death rate (per 100,000)
2.07
2019 , Modelled
(1 - 2)
Institute of Health Metrics and Evaluation (IHME). Global burden of Disease Study 2019
Mortality
HCV-related death rate (per 100,000)
5.9
2019 , Survey/reported
Politi et al J (2021). Favorable impact in hepatitis C–related mortality following free access to direct-acting antivirals in Spain. Hepatology. 00(1–10).
Diagnosed & treated
Proportion of persons living with HBV diagnosed (%)
18
2022 , Modelled
Razavi-Shearer D, Gamkrelidze I, Pan C, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The Lancet Gastroenterology & Hepatology. 2023;8(10):879-907. doi:10.1016/S2468-1253(23)00197-8
Proportion of diagnosed persons receiving appropriate HBV treatment (%) (among those eligible)
No data
Diagnosed & treated
Proportion of persons living with HCV diagnosed (%)
71
2017 , Survey/reported
Ministerio de Sanidad, Servicios Sociales e Igualidad (2020). 2 ESTUDIO DE SEROPREVALENCIA EN ESPANA. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualidad.
Proportion of diagnosed persons who have initiated HCV treatment (%)
95
2018 , Survey/reported
Ministerio de Sanidad (2020). Guia de cribado de la infeccion por el VHC. Madrid, Espana
HepB newborn vaccination
Coverage of HepB birth dose (%)
No data
Harm reduction
Number of needles-syringes per PWID per year
119
2020 , Survey/reported
European Monitoring Centre for Drugs and Drug Addiction (2019). Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe: the elimination barometer. Publications Office of the EU: Luxembourg.
Key policy indicators
HBV screening recommendations for pregnant women
Adopted
No patient co-pays for HBsAg testing
Not Adopted
Key policy indicators
National policy for harm reduction for persons who inject drugs
Adopted
No patient co-pays for anti-HCV testing
Adopted
Simplified HCV care: Non-specialists can prescribe treatment
Not Adopted
Year Value Type Source
Equity
Indicator Status Notes
Decriminalization of drug use Partially Adopted
Spain National Hepatitis Elimination Profile
National anti-discrimination law protecting persons living with hepatitis Not Adopted
Spain National Hepatitis Elimination Profile
National policy for adult HBV vaccination Adopted
Spain National Hepatitis Elimination Profile
National policy for harm reduction for persons who inject drugs Adopted
Spain National Hepatitis Elimination Profile
National policy for syringe exchange in federal prisons Adopted
Spain National Hepatitis Elimination Profile
National strategy addresses key populations Adopted
Spain National Hepatitis Elimination Profile
Prevention of mother-to-child transmission
Indicator Status Notes
Elimination of HBV mother to child transmission goal No
Spain National Hepatitis Elimination Profile
HBV screening recommendations for pregnant women Adopted
Spain National Hepatitis Elimination Profile
Universal HepB birth dose policy within 24 hrs of birth Partially Adopted
Spain National Hepatitis Elimination Profile
Strategic information
Indicator Status Notes
Estimates of HBV economic burden Not Adopted
Spain National Hepatitis Elimination Profile
National HBV prevalence survey within last 5 years Adopted
Spain National Hepatitis Elimination Profile
Routine official reporting of HBV incidence Adopted
Spain National Hepatitis Elimination Profile
Routine official reporting of HBV mortality Adopted
Spain National Hepatitis Elimination Profile
System to monitor HBV diagnosis and treatment Not Adopted
Spain National Hepatitis Elimination Profile
Financing
Indicator Status Notes
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction Not Applicable
Spain National Hepatitis Elimination Profile
Public budget line for HBV testing and treatment Adopted
Spain National Hepatitis Elimination Profile
National planning
Indicator Status Notes
HBV Action Plan No
Spain National Hepatitis Elimination Profile
HBV elimination goal Yes
Spain National Hepatitis Elimination Profile
Screening
Indicator Status Notes
HBV age-based or birth-cohort screening recommendations Not Adopted
Spain National Hepatitis Elimination Profile
HBV risk-based screening recommendations Adopted
Spain National Hepatitis Elimination Profile
HBV universal screening recommendations Not Adopted
Spain National Hepatitis Elimination Profile
No patient co-pays for HBsAg testing Not Adopted
Spain National Hepatitis Elimination Profile
Access to testing and medicines
Indicator Status Notes
Licensed point-of-care PCR testing to detect HBV Adopted
Spain National Hepatitis Elimination Profile
Treatment
Indicator Status Notes
National HBV treatment guidelines Developed
Spain National Hepatitis Elimination Profile
Simplified HBV care: No treatment co-pays Adopted
Spain National Hepatitis Elimination Profile
Simplified HBV care: Treatment and monitoring algorithm for primary care providers Not Adopted
Spain National Hepatitis Elimination Profile
Year Value Type Source
Year Value Type Source
Equity
Indicator Status Notes
Decriminalization of drug use Partially Adopted
Spain National Hepatitis Elimination Profile
Decriminalization of possession of syringes and paraphernalia Adopted
Spain National Hepatitis Elimination Profile
National anti-discrimination law protecting persons living with hepatitis Not Adopted
Spain National Hepatitis Elimination Profile
National policy for harm reduction for persons who inject drugs Adopted
Spain National Hepatitis Elimination Profile
National policy for syringe exchange in federal prisons Adopted
Spain National Hepatitis Elimination Profile
National strategy addresses key populations Adopted
Spain National Hepatitis Elimination Profile
Access to testing and medicines
Indicator Status Notes
Eligible for HCV generic medicines Not Eligible
Spain National Hepatitis Elimination Profile
Licensed point-of-care PCR testing to detect HCV Adopted
Spain National Hepatitis Elimination Profile
Registration of HCV generic medicines Not Applicable
Spain National Hepatitis Elimination Profile
Registration of HCV originator medicines Adopted
Spain National Hepatitis Elimination Profile
Strategic information
Indicator Status Notes
Estimates of HCV economic burden Adopted
Spain National Hepatitis Elimination Profile
National HCV prevalence survey within last 5 years Adopted
Spain National Hepatitis Elimination Profile
Routine official reporting of HCV incidence Adopted
Spain National Hepatitis Elimination Profile
Routine official reporting of HCV mortality Adopted
Spain National Hepatitis Elimination Profile
System to monitor HCV diagnosis and treatment Adopted
Spain National Hepatitis Elimination Profile
Financing
Indicator Status Notes
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction Not Applicable
Spain National Hepatitis Elimination Profile
Public budget line for HCV testing and treatment Adopted
Spain National Hepatitis Elimination Profile
National planning
Indicator Status Notes
HCV Action Plan Yes
Spain National Hepatitis Elimination Profile
HCV elimination goal Yes
Spain National Hepatitis Elimination Profile
Screening
Indicator Status Notes
HCV age-cohort or birth-cohort screening recommendations Not Adopted
Spain National Hepatitis Elimination Profile
HCV risk-based screening recommendations Adopted
Spain National Hepatitis Elimination Profile
HCV universal screening recommendations Not Adopted
Spain National Hepatitis Elimination Profile
No patient co-pays for anti-HCV testing Adopted
Spain National Hepatitis Elimination Profile
Prevention of mother-to-child transmission
Indicator Status Notes
HCV screening recommendations for pregnant women Not Adopted
Spain National Hepatitis Elimination Profile
Treatment
Indicator Status Notes
National HCV treatment guidelines Developed
Spain National Hepatitis Elimination Profile
Simplified HCV care: Less than 2 clinic visits during treatment Not Adopted
Spain National Hepatitis Elimination Profile
Simplified HCV care: No fibrosis restrictions Adopted
Spain National Hepatitis Elimination Profile
Simplified HCV care: No genotyping requirements Adopted
Spain National Hepatitis Elimination Profile
Simplified HCV care: No sobriety restrictions Adopted
Spain National Hepatitis Elimination Profile
Simplified HCV care: No treatment co-pays Adopted
Spain National Hepatitis Elimination Profile
Simplified HCV care: Non-specialists can prescribe treatment Not Adopted
Spain National Hepatitis Elimination Profile
Year Value Type Source
Page last updated: 19 January 2024